Place du pathologiste dans la prise en charge du carcinome rénal en situation néoadjuvante. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].

Xavier Leroy 1 Julien Edeline 2 Nathalie Rioux-Leclercq 3, *
* Auteur correspondant
3 Cancers du Rein : rôle de l'angiogenèse
IGDR - Institut de Génétique et Développement de Rennes, Service d'anatomie et cytologie pathologiques [Rennes]
Abstract : The medical treatment of renal-cell carcinoma, and of its most frequent histologic subtype, the clear cell renal-cell carcinoma, has been changed by the emergence of targeted therapies. The development of these drugs has been made possible by more precise knowledge of molecular mechanisms involved in the carcinogenesis of these tumors. Three molecular pathways may be involved in clear cell renal-cell carcinoma: VHL/HIF/VEGF, PI3K/AKT/mTOR and MAPKinases pathways. These antiangiogenic therapies are approved for the treatment of advanced and metastatic clear cell renal-cell carcinoma. In metastatic disease, pathologists have significant and different implications: 1) in tumor biopsy, only the diagnosis of clear cell renal-cell carcinoma implies the prescription of antiangiogenic drugs, and 2) after targeted therapies, pathologists must evaluate the therapeutic effects on tumor. Consensus on macroscopic and histologic reports are needed by pathologists.
Type de document :
Article dans une revue
Annales de Pathologie, Elsevier Masson, 2011, 31 (6), pp.466-71. 〈10.1016/j.annpat.2011.10.004〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00653252
Contributeur : Hervé De Villemeur <>
Soumis le : lundi 19 décembre 2011 - 10:47:08
Dernière modification le : mercredi 16 mai 2018 - 11:24:09

Identifiants

Citation

Xavier Leroy, Julien Edeline, Nathalie Rioux-Leclercq. Place du pathologiste dans la prise en charge du carcinome rénal en situation néoadjuvante. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].. Annales de Pathologie, Elsevier Masson, 2011, 31 (6), pp.466-71. 〈10.1016/j.annpat.2011.10.004〉. 〈inserm-00653252〉

Partager

Métriques

Consultations de la notice

145